A clinical case of treatment HER-2 blockers cancer therapy-related cardiac dysfunction

N.A. Kozyavin , E.A. Mureyko , M.I. Gluzman , V.S. Nikiforov

For citation:

Abstract

This clinical case about of left ventricular systolic dysfunction with chronic heart failure associated with targeted therapy with trastuzumab and pertuzumab in a patient suffering from HER-2 positive breast cancer. The exogenous phosphocreatine (“Neoton”) was added to the standard treatment of chronic heart failure with sacubitril/valsartan, bisoprolol, spironolactone or empagliflozin. It made possible to achieve an additional increase in the left ventricular ejection fraction and preventing interruption of targeted therapy and continue it as before.
Keywords: LV systolic dysfunction, cancer therapy-related cardiac dysfunction, exogenous phosphocreatine, trastuzumab, pertuzumab.

References

1. Couch LS, López-Fernández T, Lyon AR. The Ten Commandments‘ for the 2022 European Society of Cardiology guidelines on cardio-oncology. European heart journal. 2023;44(1):10-11. DOI: 10.1093/eurheartj/ehac666

2. Lyon AR, Lopez-Fernandez T et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European heart journal. Cardiovascular Imaging. 2022;23:10: 333-465.

3. Akpek M, Ozdogru I, Sahin O et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. European journal of heart failure. 2015;17(1):81-89. DOI: 10.1002/ejhf.196

4. Lyon AR, Dent S, Stanway S et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European journal of heart failure. 2020;22(11):1945-1960. DOI: 10.1002/ejhf.1920

5. Negishi K, Negishi T, Hare JL et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013;26(5):493-498. DOI: 10.1016/j.echo.2013.02.008

6. Procter M, Suter TM, de Azambuja E et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28(21):3422-3428. DOI: 10.1200/jco.2009.26.0463

7. Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005;23(31): 7820-7826. DOI: 10.1200/jco.2005.13.300

8. Curigliano G, Lenihan D, Fradley M. et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of oncology: official journal of the European Society for Medical Oncology. 2020;31(2):171-190. DOI: 10.1016/j.annonc.2019.10.023

9. Чазова И.Е., Агеев Ф.Т., Аксенова А.В. и др. Евразийские клинические рекомендации по диагностике, профилактике и лечению сердечно-сосудистых осложнений при противоопухолевой терапии. ЕКЖ. 2022;1(37). URL: https://cyberleninka.ru/article/n/evraziyskie-klinicheskie-rekomendatsii-po-diagnostike-profilaktike-i-lecheniyu-serdechno-sosudistyh-oslozhneniy-pri (дата обращения: 15.03.2024). Chazova I.E., Ageev F.T., Aksenova A.V. et al. Eurasian clinical guidelines for the diagnosis, prevention and treatment of cardiovascular complications in antitumor therapy. ECJ. 2022;1(37). URL: https://cyberleninka.ru/article/n/evraziyskie-klinicheskie-rekomendatsii-po-diagnostike-profilaktike-i-lecheniyu-serdechno-sosudistyh-oslozhneniy-pri (date of application: 03/15/2024) (in Russian).

10. Zamorano JL, Lancellotti P, Rodriguez Muñoz D. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) [published correction appears in Eur Heart J. 2016 Dec 24;:]. Eur Heart J. 2016;37(36):2768-2801. https://doi.org/10.1093/eurheartj/ehw211

11. Виценя М.В., Агеев Ф.Т., Гиляров М.Ю. и др. Злокачественные опухоли: Практические рекомендации RUSSCO. 2020;10:41. Vitsenya M.V., Ageev F.T., Gilyarov M.Yu. et al. Malignant tumors: Practical recommendations RUSSCO. 2020;10:41. https://rosoncoweb.ru/standarts/RUSSCO/2020/2020-41.pdf (in Russian).

12. Guglin M, Krischer J, Tamura R et al. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. Journal of the American College of Cardiology. 2019;73(22):2859-2868. DOI: 10.1016/j.jacc.2019.03.495

13. Pituskin E, Mackey JR, Koshman S et al. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2017;35(8):870-877. DOI: 10.1200/jco.2016.68.7830.

14. Seicean S, Seicean A, Alan N et al. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circulation Heart failure 2013;6(3):420-426. DOI: 10.1161/circheartfailure.112.000055

15. Akpek M, Ozdogru I, Sahin O. et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015;17(1):81-89. DOI: 10.1002/ejhf.196

16. Strumia E, Pelliccia F, D’Ambrosio G. Creatine phosphate: pharmacological and clinical perspectives. Advances in therapy. 2012;29(2):99-123. DOI: 10.1007/s12325-011-0091-4

17. Khoury K, Lynce F, Barac A et al. Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Res Treat. 2021;185(3):863-868. DOI: 10.1007/s10549-020-06053-y

18. Dabour MS, George MY, Daniel MR, Blaes AH, Zordoky BN. The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2024 Mar 12;6(2):159-182. DOI: 10.1016/j.jaccao.2024.01.007. PMID: 38774006; PMCID: PMC11103046.

19. CHEN Jian-kang, WANG Chun-guang Meta analysis of the protective effect of phosphocreatine on cardiotoxicity induced by anthracycline. DOI: 10.19347/j.cnki.2096-1413.201834003

20. Wang_nRCT_cardiotoxicity in ondo_300pts_2017_ch, Analysis of cardiotoxicity of Anthracyclines and relevant proposals for their clinical use. DOI: 10.3969/j.issn.1005-8982.2017.12.021

21. Li_RCT_cardiotoxicity in ondo_70pts_2-13_ch, Prevention of doxorubicin-associated cardiotoxicity by creatine phosphate sodium, 10.3969/j.issn.1672-4992.2013.03.50

22. Lin_RCT_cardiotoxicity in ondo_120pts_2010_ch, A Study of the Improvement of Quality of Life of 120 Patients With Malignant Tumors Treated with Doxorubicin-Containing Chemotherapy with Phosphonate Creatine for Injection. DOI: 10.3969/j.issn.1006-3765.2010.06.056.

For citation:Kozyavin N.A., Mureiko E.A., Gluzman M.I., Nikiforov V.S. A clinical case of treatment of systolic dysfunction of the left ventricle during targeted antitumor therapy with HER-2 blockers. Clinical review for general practice. 2024; 5 (10): 84–88 (In Russ.). DOI: 10.47407/kr2024.5.10.00500

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice